Respiratory Vaccine Research Articles

Respiratory Vaccination And Their Correlation On Incidence, And Severity Of Illness In Children Admitted To Hospital For Pneumonia

Pneumonia accounts for 14% of all deaths of children under 5 years old, killing 740 180 children in 2019. India has the second highest burden of childhood pneumonia deaths worldwide. With a child infected with Pneumonia every second, India contributes 26% of the total pneumonia cases worldwide for the period of 2019-21. In the years 2019-21, the average occurrence rate of Pneumonia in India was 2.8% according to the NHFS – 5-6. Based on the data from the Sample Registration System, the under-five mortality rate was seen to be 32 per 1000 live births. Pneumonia was identified as the second most common cause of mortality, with 19.4 percent of deaths in the age group of 1-4 years and 16.8 percent in the age group under 1yearold in India from 2016 to 2018. Prevention efforts, such as vaccination and promoting good hygiene practices, are crucial in reducing the impact of pneumonia on children's health.

Classification of the respiratory infection vaccination tweets using fuzzy logic and deep learning

Classification of the respiratory infection vaccination tweets using fuzzy logic and deep learning

Prospective clinical surveillance for severe acute respiratory illness and COVID-19 vaccine effectiveness in Kenyan hospitals during the COVID-19 pandemic.

There are limited data from sub-Saharan Africa describing the demographic characteristics, clinical features and outcome of patients admitted to public hospitals with severe acute respiratory infections during the COVID-19 pandemic. We conducted a prospective longitudinal hospital-based sentinel surveillance between May 2020 and December 2022 at 16 public hospitals in Kenya. All patients aged above 18 years admitted to adult medical wards in the participating hospitals were included. We collected data on demographic and clinical characteristics, SARS-CoV-2 infection and COVID-19 vaccination status and, admission episode outcomes. We determined COVID-19 vaccine effectiveness (VE) against admission with SARS-CoV-2 positive severe acute respiratory illness (SARI) (i.e., COVID-19) andprogression to inpatient mortality among patients admitted with SARI, using a test-negative case control design. Of the 52,636 patients included in the study, 17,950 (34.1%) were admitted with SARI. The median age was 50 years. Patients were equally distributed across sexes. Pneumonia was the most common diagnosis at discharge. Hypertension, Human Immunodeficiency Virus (HIV) infection and Diabetes Mellitus were the most common chronic comorbidities. SARS-CoV-2 test results were positive in 2,364 (27.9%) of the 8,471 patients that underwent testing. After adjusting for age, sex and presence of a chronic comorbidity, SARI patients were more likely to progress to inpatient mortality compared to non-SARI patients regardless of their SARS-CoV-2 infection status (adjusted odds ratio (aOR) for SARI and SARS-CoV-2 negative patients 1.22, 95% CI 1.10-1.37; and aOR for SARI and SARS-CoV-2 positive patients 1.32, 95% CI 1.24-1.40). After adjusting for age, sex and presence of a chronic comorbidity, COVID-19 VE against progression to inpatient mortality following admission with SARI for those with a confirmed vaccination status was 0.59 (95% CI 0.27-0.77). We have provided a comprehensive description of the demographic and clinical pattern of admissions with SARI in Kenyan hospitals during the COVID-19 pandemic period as well as the COVID-19 VE for these patients. These data were useful in providing situational awareness during the first three years of the pandemic in Kenya and informing national response measures.

Evaluating the impact of the Public Health Wales Winter Respiratory Vaccines Communication Campaign 2022–23 on vaccination uptake in Wales: an investigation using controlled interrupted time series methods

BackgroundClinically vulnerable groups are at greater risk of serious illness when seasonal flu and increased COVID-19 infection rates coincide. Public Health Wales ran a national Winter Respiratory Vaccines Communications Campaign in 2022-23, jointly targeting flu and COVID-19 vaccination uptake, tailoring messages towards low uptake groups, and eligible groups with underlying health conditions. We evaluated whether the campaign increased vaccination uptake in the clinically vulnerable using a natural experiments approach. MethodsThe study used a total population of patients registered with NHS Wales during Sept 1 to Dec 31, 2022, who were eligible for both flu and COVID19 vaccination. Anonymised data from the National Vaccination Registry in the SAIL databank was analysed using a controlled interrupted time series (CITS) to investigate the impact of the campaign on vaccine uptake. Due to the availability of data before the beginning of the campaign, COVID-19 daily rates of vaccination were used. The campaign intervention group contained respiratory clinically vulnerable patients aged 16–49 years (n=49 749) and the control group was patients not clinically vulnerable but eligible because of age ≥50 years. The preintervention time series was 1 to 26 September 2022 and post campaign data was examined in the initial weeks after campaign introduction. Modelling will take account of COVID-19 infections, vaccination invitation letters and consider demographics. FindingsDescriptive trends in vaccination uptake show age is a dominating factor over clinical risk for people taking up the vaccine offer, particularly as age rises towards 65+ years. Early findings from the CITS suggest an increase in vaccination uptake from the campaign. InterpretationWe outline the practical application of using novel methods to evaluate the impact of a national communications campaign on vaccine uptake. Confidently attributing the effect of the campaign is challenging due to the complex vaccination delivery landscape, with results requiring careful interpretation. FundingNone.

Cost-effectiveness of respiratory syncytial virus adjuvanted vaccine in Portuguese aged ≥ 60 years

Abstract Background Respiratory syncytial virus (RSV) infections are one of the leading causes of lower respiratory tract disease among adults aged ≥60 years in Europe. This study aims to assess the potential public health impact of the RSVPreF3 OA adjuvanted vaccine, the first approved preventive intervention for the older adult population in Portugal. Methods A monthly-cycle static Markov model was developed to assess RSVPreF3 OA adjuvanted vaccine impact on adults aged 60 years and older in Portugal. A single dose of RSVPreF3 OA adjuvanted vaccine was compared to no-vaccination over a three-year time-horizon. The model captures lower respiratory tract disease (LRTD) RSV cases, hospitalizations, deaths, and healthcare resource utilization. Data inputs were based on local published literature, supplemented by the best available data when local information was lacking. Results Based on preliminary analysis considering 75% vaccine coverage, model outputs estimate that RSVPreF3 OA adjuvanted vaccine can prevent 71,433 LRTD cases requiring medical attendance, 11,067 hospitalizations, 1,793 intensive care unit admissions and 1,003 deaths. The model estimates that 32 adults need to be vaccinated to avoid one RSV LRTD case, 207 adults need to be vaccinated to avoid one hospitalization and 2,283 adults need to be vaccinated to avoid one death. The incremental cost-effectiveness ratio was estimated at 9,541€, hence the RSVPreF3 OA adjuvanted vaccine is cost-effective compared to no vaccination. Conclusions The results demonstrate a strong preventive impact of the RSVPreF3 OA adjuvanted vaccine on health outcomes and healthcare resource utilization in adults ≥60 years, leading to a significant public health benefit. This result emphasizes the importance of preventing RSV to preserve the health and well-being of Portugal’s older adults. In addition, data from ongoing studies may enhance precision and extensive sensitivity analyses validate the robustness of the model’s input assumptions. Key messages • This study shows the robust evidence of RSVPreF3 OA adjuvanted vaccine to improve public health by preventing thousands of hospitalizations and deaths among ≥60 years, in Portugal. • Vaccinating adults aged ≥ 60 years with RSVPreF3 OA adjuvanted vaccine in Portugal is a cost-effective strategy.

Recurrent Respiratory Papillomatosis in the Post–Human Papillomavirus Vaccination Era

This cross-sectional study examines the incidence of juvenile-onset recurrent respiratory papillomatosis and HPV vaccination rates from 2007 to 2022 in the US.

PSIV-4 Effectiveness of maternal bovine appeasing substance on growth, physiological, and behavioral responses of high-risk stocker cattle

Abstract Stocker cattle purchased at auction can be susceptible to disease due to the stressors associated with the auction process. These cattle are labeled “high-risk” due to their decreased immune system during transportation, handling, and vaccination processes. The objective of this study was to determine the efficacy of a maternal bovine appeasing substance, FerAppease, on growth performance and fearfulness of stocker cattle. Male beef calves (n = 80) were purchased at auction and transported to the University of Arkansas Division of Agriculture Savoy Research Complex Beef Stocker Unit. Steers and bulls were of varying age, breed, and temperament. Upon arrival to the facility (d 0), bulls (n = 48) were castrated by banding and cattle were assigned to 8 pens (n = 10 calves/pen; 4 bulls and 6 steers/pen). On d 0, cattle in 4 pens were treated with FerAppease (FA) on the nuchal skin (n = 40) and cattle in the other 4 pens were not treated and served as controls (CON, n = 40). All cattle received commercial clostridial and respiratory vaccines and were treated with an anthelmintic. Cattle were offered bermudagrass hay for ad libitum intake and were fed a grain supplement (1.8 kg/d) to meet or exceed nutrient requirements. To measure growth performance, body weight (BW) was recorded on d 0, 3, 14, 28, 41, 42 of the study and used to calculate average daily gain (ADG). Body weights on d 41 and 42 were averaged to calculate final BW. To measure fearfulness, exit chute velocity (ECV) was measured with a rodeo timer and recorded on d 3, 14, 28, 41, and 42. To measure inflammation, blood was collected from 5 calves/pen (n = 3 bulls and 2 steers/pen) on d 0, 3, 28 and 42 and haptoglobin (Hp) was measured in blood serum. A two-way ANOVA with the fixed effects of sex (arrived as steer or bull) and treatment (FA, CON) and random effect of pen was used for analysis. Serum Hp was log transformed to improve normality. There was not a treatment effect on any of the measures collected. Steers had a greater BW throughout the study (P ≤ 0.05), weighing more than bulls at the end of the study (261 kg vs 241 kg, respectively). Steers also had a greater (P < 0.0001) ADG than bulls (1.14 vs. 0.84 kg/d, respectively). On d 3 and 14, steers exited the chute more rapidly (P < 0.05) than bulls. There was an interactive effect on serum d 28 Hp concentrations (P = 0.04), where CON bulls had greater Hp concentrations (111,261 ng/mL) than CON steers (13,055 ng/mL), with FA steers and bulls intermediate. The results from this study indicate that there was no consistent effect of the treatment on the measures collected.

Humoral immunity and safety of respiratory virus vaccines in systemic lupus erythematosus population: a meta-analysis based on twenty-five observational studies

Background Systemic lupus erythematosus (SLE), an extensive autoimmune disorder, compromises viral resistance and alters immune responses post respiratory virus vaccines. This study aims to assess immune response levels and safety in SLE patients following respiratory virus vaccines. Methods Extensive searches, until 1 March 2024, were conducted using PubMed, EMBASE, and Cochrane Library. Outcomes, encompassing seroconversion rate (SCR), antibody and IgG titers, neutralizing antibodies, anti-spike antibodies, anti-receptor binding domain (RBD) IgG, and adverse events, were appraised. Results Sixteen articles, comprising 25 observational studies, were included. SLE patients exhibited lower SCR (OR = 0.42, 95%CI: 0.26 to 0.69), antibody titers (SMD=-2.84, 95%CI: −3.36 to −1.61), and neutralizing antibodies (OR = 0.27, 95%CI: 0.13 to 0.56) compared to the healthy population post respiratory virus vaccines. Notably, differences were statistically insignificant for anti-RBD IgG (OR = 1.75, 95%CI: 0.10 to 29.42), IgG titers (SMD=-2.54, 95%CI: −5.57 to −0.49), anti-spike antibodies (OR = 0.35, 95%CI: 0.08 to 1.53), injection site discomfort (OR = 1.03, 95%CI: 0.52 to 2.06), fatigue (OR = 1.23, 95%CI: 0.74 to 2.03), fever (OR = 1.02, 95%CI: 0.64 to 1.63), localized reactions (OR = 0.69, 95%CI: 0.37 to 1.30), systemic reactions (OR = 1.00, 95%CI: 0.59 to 1.69), allergic reactions (OR = 5.11, 95%CI: 0.24 to 107.10), self-reported vaccination-related adverse events (OR = 1.61, 95%CI: 0.56 to 4.63), and disease flares after vaccination (OR = 1.00, 95%CI: 0.14 to 7.28). Conclusion Despite the reduced immune response and host protection in SLE patients post-Corona Virus Disease 2019 (COVID-19) and influenza vaccines compared to the healthy population, safety profiles are comparable. Therefore, it is recommended that SLE patients receive COVID-19 and influenza viral vaccines to fortify their resistance.

Evidence base for yearly respiratory virus vaccines: Current status and proposed improved strategies.

Annual vaccination is widely recommended for influenza and SARS-CoV-2. In this essay, we analyse and question the prevailing policymaking approach to these respiratory virus vaccines, especially in the United States. Every year, licensed influenza vaccines are reformulated to include specific strains expected to dominate in the season ahead. Updated vaccines are rapidly manufactured and approved without further regulatory requirement of clinical data. Novel vaccines (i.e. new products) typically undergo clinical trials, though generally powered for clinically unimportant outcomes (e.g. lab-confirmed infections, regardless of symptomatology or antibody levels). Eventually, the current and future efficacy of influenza and COVID-19 vaccines against hospitalization or death carries considerable uncertainty. The emergence of highly transmissible SARS-CoV-2 variants and waning vaccine-induced immunity led to plummeting vaccine effectiveness, at least against symptomatic infection, and booster doses have since been widely recommended. No further randomized trials were performed for clinically important outcomes for licensed updated boosters. In both cases, annual vaccine effectiveness estimates are generated by observational research, but observational studies are particularly susceptible to confounding and bias. Well-conducted experimental studies, particularly randomized trials, are necessary to address persistent uncertainties about influenza and COVID-19 vaccines. We propose a new research framework which would render results relevant to the current or future respiratory viral seasons. We demonstrate that experimental studies are feasible by adopting a more pragmatic approach and provide strategies on how to do so. When it comes to implementing policies that seriously impact people's lives, require substantial public resources and/or rely on widespread public acceptance, high evidence standards are desirable.

Field efficacy of a novel porcine reproductive and respiratory syndrome modified-live virus vaccine with an emphasis on growth performance.

This field evaluation was designed to evaluate the efficacy of a new porcine reproductive and respiratory syndrome virus-2 (PRRSV-2) modified live virus vaccine at three independent pig farms. Three farms were selected for this study based on their respiratory disease status caused by PRRSV-2 infection in post-weaning and growing pigs. Each farm housed a total of 40, 18-day-old pigs that were randomly allocated to one of two treatment groups. Pigs were administered a 1.0mL dose of the bivalent vaccine intramuscularly at 21 days of age in accordance with the manufacturer's recommendations, whereas unvaccinated pigs were administered a single dose of phosphate buffered saline at the same age. Vaccinated groups were measured and calculated significantly (p<0.05) higher in body weight and average daily weight gain on all three farms compared with unvaccinated groups. Vaccinated groups elicited PRRS antibodies and PRRSV-2-specific interferon-γ secreting cells, which reduced the amount of PRRSV-2 genomic copies in the blood and reduced macroscopic and microscopic lung lesions severity when compared with unvaccinated groups. The field evaluation data demonstrated that a new PRRSV-2 modified live virus vaccine was efficacious in swine herds suffering from respiratory diseases caused by PRRSV-2 infection.

Severe acute respiratory syndrome coronavirus-2 mRNA vaccine

Severe acute respiratory syndrome coronavirus-2 mRNA vaccine

Protective evaluation of the commercialized porcine reproductive and respiratory syndrome virus vaccines in piglets challenged by NADC34-like strain.

In China, the porcine reproductive and respiratory syndrome virus (PRRSV) has undergone several variations over the decades and contributed to the diversity of the clinical epidemic PRRSV strains. This has complicated the prevention and control of PRRS. In particular, the efficacy of the currently available commercial vaccines against the highly pathogenic NADC34-like strains is unclear. Therefore, the objective of this study was to evaluate the protection efficacy of three commercial PRRS modified-live virus (MLV) vaccines derived from classical PRRS VR2332 MLV and R98 MLV against challenge with a heterologous NADC34-like PRRSV strain, JS2021NADC34, which has high pathogenicity in pigs. PRRSV- and antibody-free piglets were immunized with the PRRS VR2332 MLV vaccine or either of two R98 MLV vaccines (from different manufacturers) and were challenged with the JS2021NADC34 strain 28 days after immunization. Rectal temperature, clinical symptoms, viremia and viral shedding from the nose, gross lesions in the thymus and lungs, microscopic lesions and viral distribution in the lungs, as well as the humoral immune response and mortality rates were recorded over a 14-day post-challenge period. The results showed that PRRS VR2332 MLV had better efficacy against the JS2021NADC34 challenge than PRRS R98 MLV, with vaccinated piglets in the former group showing transient and mild symptoms, mild pathological lesions in the lungs, mild thymic atrophy, and low viral levels in sera and nasal swabs, as well as better growth performance and a 100% survival rate. In contrast, two PRRS R98 MLVs exhibited limited efficacy against the JS2021NADC34 challenge, with the piglets in two R98 groups showing obvious clinical symptoms and pathological changes in the lungs and thymus; moreover, there were two deaths caused by PRRS in two R98 groups, respectively. Despite this, the mortality rate was lower than that of the unvaccinated piglets that were challenged with JS2021NADC34. The cumulative results demonstrate that PRRS VR2332 MLV was partly effective against the highly pathogenic PRRSV NADC34-like strain based on the observations over the 14-day post-challenge period. Thus, it might be a viable option among the commercially available vaccines for control of NADC34-like virus infections in swine herds.

Respiratory Vaccination Rates in People Living With Spinal Cord Injury/Disorder in Switzerland: A Descriptive Analysis of Coverage and Vaccine Hesitancy.

The aim of the study is to provide a population-based evaluation of vaccination coverage to prevent respiratory complications from SARS-COV-2, influenza, and pneumococcus, among community-dwelling persons with spinal cord injury/disease. This is a cross-sectional survey conducted in 2022, utilizing questionnaires administered to persons with spinal cord injury/disease living in Switzerland. Main outcomes were ever-vaccination rates for SARS-COV-2, influenza, and pneumococcus. Secondary outcomes included demographics, lesion and education levels, as well as respiratory and cardiovascular conditions. Vaccine hesitancy was additionally assessed for all three vaccines in nonvaccinated persons through questions on reasons for not getting vaccinated. A total of 1158 persons participated in this survey. Overall vaccination rates were highest for SARS-COV-2 86.5% (95% CI = 84.4-88.3), followed by influenza 44.6 (41.7-47.6) and pneumococcus: 7.5% (6.0-9.3). The most prominent reasons for not being vaccinated were doubt on effectiveness (72.7%) and potential side effects (60%) for SARS-COV-2, patients did not feel at risk for influenza (57%) and insufficient information from the physician (52.4%) for pneumococcus vaccination. In individuals with spinal cord injury/disease, vaccination coverage is notably low for influenza and especially pneumococcus. Vaccine hesitancy varies between vaccination types and is associated with vaccine-specific reasons. These findings underscore the imperative for updated clinical vaccination guidelines, improved public health information, and targeted intervention programs for specific patient groups.

Safety Assessment of Concurrent Vaccination with the HPV Vaccine and the COVID-19 Vaccine in Fujian Province, China: A Retrospective Study.

During acute respiratory infections, women may concurrently receive human papillomavirus (HPV) and respiratory vaccines, as observed during the coronavirus disease 2019 (COVID-19) pandemic in China. However, few studies have assessed the safety of such concurrent administration, which could impact HPV vaccination schedules. This study analyzes the safety and optimal sequence of concurrent HPV and COVID-19 vaccinations. For this purpose, we surveyed women with both vaccines from January to October 2023 in Fujian Province, China. During this process, we collected vaccination history and adverse event (AE) data via telephone or interviews. Participants were grouped as Before, Concurrent, or After based on their vaccination sequence. A Chi-squared test, exact Fisher tests, and logistic regression were used to analyze the incidence of AEs and factors influencing vaccine safety. Overall, 1416 eligible participants were included. Although overall AE risk with the HPV vaccine was unaffected by vaccination sequence, individual AEs varied statistically between groups, including pain at the vaccination site (p < 0.001) and prolonged menstruation duration (p = 0.003). Based on the results, the optimal sequence would be to receive the HPV vaccine after the COVID-19 vaccine (After group). This insight may guide future emergency vaccination sequences for HPV and other respiratory infectious diseases.

Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines.

In the post-COVID-19 era, the co-circulation of respiratory viruses, including influenza, SARS-CoV-2, and respiratory syncytial virus (RSV), continues to have significant health impacts and presents ongoing public health challenges. Vaccination remains the most effective measure for preventing viral infections. To address the concurrent circulation of these respiratory viruses, extensive efforts have been dedicated to the development of combined vaccines. These vaccines utilize a range of platforms, including mRNA-based vaccines, viral vector vaccines, and subunit vaccines, providing opportunities in addressing multiple pathogens at once. This review delves into the major advancements in the field of combined vaccine research, underscoring the strategic use of various platforms to tackle the simultaneous circulation of respiratory viruses effectively.

Pneumococcal and Influenza Vaccination Coverage in Patients with Heart Failure: A Systematic Review.

Background/Objectives: As heart failure (HF) patients face increased vulnerability to respiratory infections, optimizing pneumococcal and influenza vaccination coverage becomes pivotal for mitigating additional health risks and reducing hospitalizations, morbidity, and mortality rates within this population. In this specific subpopulation of patients, vaccination coverage for pneumococcal and influenza holds heightened significance compared to other vaccines due to their susceptibility to respiratory infections, which can exacerbate existing cardiovascular conditions and lead to severe complications or even death. However, despite the recognized benefits, vaccination coverage among HF patients remains below expectations. The aim of the present systematic review was to assess the vaccination coverage for influenza and pneumococcus in HF patients from 2005 to 2023 and the vaccination's effects on survival and hospitalizations. Methods: The authors developed the protocol of the review in accordance with the PRISMA guidelines, and the search was performed in databases including PubMed and Scopus. After the initial search, 851 studies were found in PubMed Library and 1961 in Scopus (total of 2812 studies). Results: After the initial evaluation, 23 publications were finally included in the analysis. The total study population consisted of 6,093,497 participants. Regarding the influenza vaccine, vaccination coverage ranged from low rates of 2.5% to very high rates of 97%, while the respective pneumococcal vaccination coverage ranged from 20% to 84.6%. Most studies demonstrated a beneficial effect of vaccination on survival and hospitalizations. Conclusions: The present systematic review study showed a wide variety of vaccination coverage among patients with heart failure.

Yeast β-glucan promotes antiviral type I interferon response via dectin-1

Pseudorabies virus (PRV), an alphaherpesvirus, is a neglected zoonotic pathogen. Dectin-1 sensing of β-glucan (BG) induces trained immunity, which can possibly form a new strategy for the prevention of viral infection. However, alphaherpesvirus including PRV have received little to no investigation in the context of trained immunity. Here, we found that BG pretreatment improved the survival rate, weight loss outcomes, alleviated histological injury and decreased PRV copy number of tissues in PRV-infected mice. Type I interferons (IFNs) including IFN-α/β levels in serum were significantly increased by BG. However, these effects were abrogated in the presence of Dectin-1 antagonist. Dectin-1-mediated effect of BG was also confirmed in porcine and murine macrophages. These results suggested that BG have effects on type I IFNs with antiviral property involved in Dectin-1. In piglets, oral or injected immunization with BG and PRV vaccine could significantly elevated the level of PRV-specific IgG and type I IFNs. And it also increased the antibody levels of porcine reproductive and respiratory syndrome virus vaccine and classical swine fever vaccine that were later immunized, indicating a broad-spectrum effect on improving vaccine immunity. On the premise that the cost was greatly reducing, the immunological effect of oral was better than injection administration. Our findings highlighted that BG induced type I IFNs related antiviral effect against PRV involved in Dectin-1 and potential application value as a feed additive to help control the spread of PRV and future emerging viruses.

94 Effects of orally administered Megasphaera elsdenii during finishing diet realimentation on feedlot steer fecal consistency, clinical depression, and rumination

Abstract The objective of the study was to determine the effects of oral administration of Megasphaera elsdenii NCIMB 41125 (ME) during finishing diet realimentation on fecal consistency, clinical depression, and rumination of feedlot steers. Steers [n = 60; initial body weight (BW) = 591 kg ± 38 kg] were assigned to microbial supplement treatment in a randomized complete block design. Treatments were 1) no ME (CON); and 2) orally administered microbial supplement (1 x 1010 colony forming units ME/capsule; LP) immediately before diet reintroduction. Preceding study initiation, steers consumed a finishing diet with 88% concentrate [dry matter (DM) basis] primarily consisting of whole shelled corn and corn silage for 200 d. Steers were transported from a local feedyard 27 km and upon arrival offered ad libitum long stem hay. Forty-eight h after arrival, steers were reintroduced to a 90% concentrate (DM basis) finishing diet with consisting of dry-rolled corn, dried distiller’s grains plus solubles, liquid supplement, and wheat hay. The diet was introduced initially at 1.5% BW on 0 d, and daily delivery was increased until cattle reached their intake plateau at which point a slick bunk management system was employed. At initial processing, all steers received respiratory and clostridial vaccines and were fitted with wireless rumination tags to track daily rumination throughout the 42-d study. Fecal consistency (FCS) and clinical depression scores (CD) were collected starting 24 h after diet initiation, and subsequent collections occurred at 24 h intervals until 168 h. Fecal consistency was recorded on 20 random pen surface fecal samples and CD was recorded for individual steer. Categorical distributions for FCS and CD were analyzed with the Fisher’s Exact Test. Rumination data was analyzed as a linear mixed model with fixed effects of treatment, days on feed (DOF), and their interaction with a random effect of block and DOF as a repeated measure. For all analyses, P ≤ 0.05 was declared significant and 0.05 &amp;gt; P ≤ 0.10 was considered a tendency. No difference (P ≥ 0.49) was observed for CD at all time points. Additionally, no difference (P ≥ 0.12) was observed for FCS at 24, 48, 72, 120, 144, and 168 h. Fecal consistency tended (P = 0.10) to differ at 96 h, with CON exhibiting a 67% decrease in FCS 1 and 2. No significant (P ≥ 0.78) treatment × DOF interaction was noted for daily minutes ruminating. A significant (P &amp;lt; 0.01) DOF effect was realized for daily minutes ruminating. Minutes ruminating differed (P &amp;lt; 0.01) between treatments, with CON steers ruminating 6% more minutes daily than LP steers. Oral administration of ME had minimal effects on FCS and CD and decreased daily rumination time in feedlot steers during finishing diet realimentation.

Transition from one commercial porcine reproductive and respiratory syndrome modified-live virus vaccine to another in a breeding herd and impact on productivity

Porcine reproductive and respiratory syndrome (PRRS) continues to represent a significant cost to the swine industry and efforts are focused on prevention and mitigation of losses across production phases. Herein describes a PRRS modified-live virus (MLV) vaccinated breeding herd that changed commercial MLV vaccines to improve post-weaning performance. Two whole-herd vaccinations with a new PRRS MLV vaccine, administered 4 weeks apart, occurred without breeding herd production disruptions and with limited changes in diagnostic results. Replacement gilts tested PRRS virus negative 10 weeks post vaccination with the new MLV vaccine. Diagnostics were intermittently positive in the breeding herd and early nursery.

Respiratory Syncytial Vaccination: Parents' Willingness to Vaccinate Their Children.

This study was conducted to assess parents' willingness to vaccinate their children with the RSV vaccine and the key predictors of this intention among parents in Italy. Data were collected using an anonymous self-administered questionnaire from April to November 2023, targeting parents in public kindergartens and nursery schools in southern Italy. The survey assessed parents' socio-demographic characteristics, health-related details, their child's health status, attitudes toward RSV infection and its vaccine, and their source(s) of information. A total of 404 parents agreed to participate in the study. Only 18.2% of participants were very concerned that their children could get infected by RSV, and this concern was more likely among parents whose child had been diagnosed with bronchiolitis, those who received information from HCWs, those who had heard of RSV, and those who needed additional information. Almost half (51.3%) were willing to vaccinate their child, and this inclination was more likely among fathers, employed parents, those with daughters, those who had heard of RSV, those who received information from HCWs, and those who needed additional information. An educational campaign regarding a future RSV vaccine, especially about its safety and efficacy, is needed in order to improve parents' willingness.